Welcome to our dedicated page for Immunoprecise news (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on Immunoprecise stock.
ImmunoPrecise Antibodies Ltd (IPA) delivers cutting-edge antibody solutions through AI-enhanced multi-omics modeling and proprietary biotechnologies. This news hub provides investors and researchers with essential updates on corporate developments, scientific breakthroughs, and strategic partnerships driving innovation in therapeutic antibody discovery.
Access timely reports on IPA's R&D milestones, regulatory progress, and technology advancements. Our curated collection features press releases covering key areas including patent filings, collaborative research initiatives, and platform enhancements within the antibody development lifecycle.
Stay informed about IPA's role in advancing precision immunology through updates on their custom antibody services, AI-driven discovery platforms, and client-focused solutions for pharmaceutical and academic partners. Bookmark this page for direct access to verified corporate communications and scientific progress reports.
ImmunoPrecise Antibodies (NASDAQ: IPA) has expressed strong support for the FDA's decision to phase out animal testing requirements for monoclonal antibodies and pharmaceutical products. The company's AI platform, LENSai™, aligns with this regulatory shift by providing validated AI-driven methodologies that support New Approach Methodologies (NAMs).
The platform offers three key capabilities:
- Safety and Toxicity Prediction through AI analytics mapping drug interactions across the human proteome
- Immunogenicity Screening to identify immune response risks and optimize patient strategies
- Knowledge Graphs for Drug Efficacy that integrate biological data for precise drug interaction predictions
According to CEO Dr. Jennifer Bath, this transition aims to streamline preclinical workflows, reduce development costs, and maintain higher ethical standards while ensuring regulatory compliance.
ImmunoPrecise Antibodies (IPA) reported Q3 FY25 financial results, securing an $8-10M strategic partnership for co-developing Antibody-Drug Conjugates and bispecific antibodies. The company expanded AI infrastructure through collaborations with Vultr and GPU technology providers.
Key financial highlights include:
- Revenue remained stable at $6.2M
- BioStrand showed 131.8% YoY revenue growth with 97% gross margin
- Net loss of $21.5M ($0.66 per share) vs $2.7M loss in FY24 Q3
- Cash position of $12.9M as of January 31, 2025
Notable developments include headquarters relocation to Austin, Texas, completion of an $8.8M ATM equity raise, and full conversion of Yorkville debenture. The company recorded a $21.2M impairment charge related to BioStrand's intangible assets.
ImmunoPrecise Antibodies (NASDAQ: IPA) has entered into a strategic partnership with a leading biotechnology company to develop Antibody-Drug Conjugates (ADCs) and bispecific antibodies for cancer treatment. The collaboration, valued at $8 million with potential expansion to $10 million, will span 18-24 months.
The partnership integrates IPA's proprietary B-cell Select™ platform and AI-driven discovery capabilities to enhance therapeutic development efficiency. The scope includes discovery, lead characterization, optimization, and preclinical-grade production of multiple antibody-based therapeutics, focusing on developing highly selective cancer treatments.
The project combines IPA's multi-omics AI-driven modeling and discovery platform with B-cell Select™ technology to optimize therapeutic selection and accelerate lead development. Work has already commenced, utilizing IPA's proprietary platforms including LENSai™ technology to advance targeted cancer therapeutics development.
ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-powered antibody discovery and development company, has announced the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. The release date has been moved from March 13 to March 28, 2025, with an earnings call scheduled for 10:30 AM Eastern Time on the same day.
The delay is attributed to providing additional time for auditors to complete necessary reviews and audit requirements, specifically focusing on valuation calculations of goodwill and intangible assets. This extension aims to ensure accurate financial data representation and full regulatory compliance.
ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-powered antibody discovery and development company, has scheduled its third quarter fiscal year 2025 financial results announcement and business update for March 13, 2025. The company will release its financial results via press release followed by a conference call and webcast at 10:30 AM ET.
The earnings call will include a management presentation and a Q&A session. Participants can join through various channels including USA/International toll line (+1-646-307-1963) or toll-free numbers (800-715-9871 for USA and Canada) using Conference ID 3224490. A webcast will be available through the company's IR events page.
ImmunoPrecise Antibodies (NASDAQ: IPA) has announced a strategic collaboration with RIBOPRO to enhance therapeutic antibody discovery by combining RIBOPRO's mRNA and lipid nanoparticle (LNP) technologies with IPA's AI-powered discovery capabilities.
The partnership aims to overcome challenges in antigen expression during antibody discovery by utilizing RIBOPRO's expertise in mRNA sequence optimization and LNP-based delivery alongside IPA's advanced B-cell screening, single-cell analysis, and deep-learning AI workflows.
This integration of mRNA immunization into IPA's discovery pipeline is expected to improve antigen presentation and immune responses, potentially accelerating the development of novel therapeutics.
ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-driven biotherapeutic research company, has announced significant leadership changes. Dr. Kamil Isaev, a technology leader with over 30 years of expertise in AI and semiconductor technologies, has joined the Board of Directors. Isaev currently serves as a Venture Partner at ABRT VC, leading their AI Lab and VC Score project, and has previously held key positions at Intel, Dell EMC, and Align Technology.
The company has also appointed Joseph Scheffler as Interim Chief Financial Officer. Scheffler brings over 20 years of experience in financial management, most recently serving as Interim Corporate Controller at Nidec - Kinetek, where he managed consolidated financial reporting for a $400 million global manufacturing firm. Additionally, Chris Buyse has stepped down from the Board of Directors following his tenure during the company's transitional phase.
ImmunoPrecise Antibodies (NASDAQ: IPA) has received approval from Nasdaq Listing Qualifications to transfer its securities from the Nasdaq Global Market to the Nasdaq Capital Market. This strategic move, effective February 21, 2025, grants IPA an additional 180-day compliance period until August 18, 2025, to meet the minimum bid price requirement of $1.00 per share. The transfer allows the company to maintain its Nasdaq listing while continuing to execute its strategic initiatives.
ImmunoPrecise Antibodies (NASDAQ: IPA) has completed two significant financial initiatives: a USD $8.8 million at-the-market (ATM) equity offering program, generating USD $7.0 million in gross proceeds, and the full conversion of its Yorkville Advisors debenture into common shares.
The company strategically utilized the ATM program to reduce capital costs while strengthening its financial position. The full conversion of the Yorkville debenture eliminates near-term debt obligations, further improving IPA's balance sheet.
According to CEO Dr. Jennifer Bath, these developments demonstrate investor confidence in IPA's vision and technology. The enhanced financial position will support the company's growth strategy and advancement of its AI-powered therapeutic discovery platform, LENSai.
ImmunoPrecise Antibodies (NASDAQ: IPA) has developed a new class of GLP-1 therapies using artificial intelligence through its proprietary LENSai™ platform. The AI-designed therapeutics aim to improve current diabetes and obesity treatments by enhancing efficacy, safety, and patient satisfaction.
The company's innovation focuses on creating GLP-1-like alternatives with potential advantages including increased patentability, extended stability, improved administration routes, reduced dosing requirements, and more efficient manufacturing methods. IPA is exploring transdermal delivery as a non-invasive alternative to injections.
In just two weeks, LENSai generated and optimized novel genetic sequences for GLP-1-like constructs. The company is collaborating with Aldevron, to optimize its alternatives for nucleic acid-based expression systems. The AI-driven approach incorporates optimized genetic elements to explore long-term, stable therapeutic production within the body during pre-clinical investigations.
